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Raloxifene hydrochloride (RLX) is a selective estrogen receptor modulator that be-
longs to the benzothiophene class of compounds (Fig. 1) (1). Its chemical designation is
methanone[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)etho-
xy]phenyl]hydrochloride. RLX is used for prevention of osteoporosis in postmenopausal
women.
A few HPLC methods with UV detection have been previously reported for the de-
termination of RLX in pharmaceuticals (2–7). Other techniques reported for the assay of
RLX in pharmaceuticals include UV and VIS spectrophotometry (8–10), capillary electro-
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A rapid, sensitive and selective method for the determi-
nation of raloxifene hydrochloride (RLX) in pure drug
and in tablets was developed using gradient high perfor-
mance liquid chromatography (HPLC). The devised me-
thod involved separation of RLX on a reversed phase Hy-
persil ODS column and determination with UV detection
at 284 nm. The standard curve was linear (R = 0.999) over
the concentration range of 50–600 mg mL–1with a detec-
tion limit of 0.04 mg mL–1 and a quantification limit of
0.16 mg mL–1. Intra-day and inter-day precision and ac-
curacy of the method were established according to the
current ICH guidelines. Intra-day RSD values at three QC
levels (250, 450 and 550 mg mL–1) were 0.2–0.5%, based on
the peak area. The intra-day relative error (er) was be-
tween 0.2 and 0.5%. The developed method was success-
fully applied to the determination of RLX in tablets and
the results were statistically compared with those obta-
ined by a literature method. Accuracy, evaluated by means
of the spike recovery method, was the excellent with per-
cent recovery in the range 97.7–103.2 with precision in the
range 1.6–2.2%. No interference was observed from the co-
formulated substances. The method was economical in
terms of the time taken and the amount of solvent used.
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phoresis (11) and Rayleigh scattering (11). Some of the reported methods, however, suf-
fer from such disadvantages as poor selectivity, sensitivity, accuracy and precision (Table
I).
This paper deals with the development and validation of a sensitive gradient HPLC
method for the assay of RLX in pharmaceuticals. Separation and determination were done
on a reversed phase Hypersil C18 column and UV-detection at 284 nm.
EXPERIMENTAL
Apparatus
The chromatographic system consisted of an Agilent 1100 series chromatograph
equipped with an in-built solvent degasser, quaternary pump, photo diode array detec-
tor with variable injector and auto sampler, and a reversed phase 5-mm Hypersil ODS
column (250 ´ 4.6 mm i.d.).
Reagents and standards. – All chemicals used were of analytical reagent grade. Am-
monium acetate and acetic acid (from s.d. Fine Chem. Ltd, India) and HPLC grade ace-
tonitrile (from Merck. Ltd, India) were used. Distilled water filtered through a 0.45 mm
filter (Millipore, India) was used to prepare solutions. A diluent consisting of 60% aceto-
nitrile and 40% water (V/V) was used to prepare the sample preparations.
A 0.154% ammonium acetate (m/V) solution, pH adjusted to 4.0 with acetic acid,
was the mobile phase A and acetonitrile was the mobile phase B.
Pharmaceutical grade RLX, certified to be 99.8% pure, was procured from Cipla In-
dia Ltd, India, and was used as received. For the study, an accurately weighed 50 mg of
RLX was dissolved and diluted to the volume with the diluent solution in a 50 mL cali-
brated flask to obtain a concentration of 1000 mg mL–1 RLX.
Procedures
Chromatographic conditions. – Separation was achieved at ambient temperature on
the column using the mobile phase at a flow rate of 1.2 mL min–1. The detector wave-
length was set at 284 nm with sensitivity of 0.2 a.u.f.s.
Gradient composition was as follows:
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Fig. 1. Structure of raloxifene
hydrochloride.
Time (min) 0 30 35 40 45
A (%) 50 10 10 50 50
B (%) 50 90 90 50 50
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Calibration. – Working standard solutions equivalent to 50 to 600 mg mL–1 RLX were
prepared by appropriate dilution of the stock standard solution (1000 mg mL–1) with the
diluent solution. Twenty-mL aliquot of each solution was injected automatically onto the
column in duplicate and the chromatograms were recorded. Calibration graph was pre-
pared by plotting the mean peak area vs. RLX concentration.
The concentration of the unknown was read from the calibration graph or computed
from the regression equation derived from the mean peak area-concentration data.
Assay in dosage forms. – The following formulations containing RLX were purchased
from local commercial sources and used in the investigation: A, Fiona tablets (Dr. Reddys
Ltd, India) containing 60 mg of RLX, B, Gynista tablets (Micro Nova Ltd, India) contain-
ing 60 mg of RLX per tablet and C. Ronal tablets (Blue Cross Ltd, India) containing 60
mg of RLX.
A quantity of tablet powder equivalent to 100 mg of RLX was accurately weighed
into a 100 mL calibrated flask, 60 mL of diluent solution was added and the content was
shaken for 20 min; the volume was then diluted to the mark and mixed well. A small
portion of the extract (say, 10 mL) was withdrawn and filtered through a 0.2-mm filter to
ensure the absence of particulate matter. The filtered solution was appropriately diluted
with the diluent solution for analysis as already described.
Recovery experiment. – To a fixed and known amount of the drug in tablet powder
(pre-analyzed), pure RLX was added at three different levels, and the total was found by
the proposed methods from which the percent recovery of pure drug added was calculated.
Selectivity testing. – A separate selectivity test was performed by applying the pro-
posed methods to the determination of RLX in a synthetic mixture consisting of RLX,
talc, starch, lactose, calcium gluconate, calcium dihydrogenorthophosphate, sodium algi-
nate and magnesium stearate, in the mass ratio of 1: 2.5: 3.0: 0.3: 0.5: 0.2: 0.7: 1 RLX was
extracted with three 20-mL portions of diluent and filtered. The filter was washed with
diluent; the filtrate and washings were collected in a 100-mL calibrated flask and diluted
to the volume with diluent and mixed well. An appropriate aliquot of the extract was
subjected to analysis as stated earlier.
RESULTS AND DISCUSSION
Method development
A solution of RLX was injected in duplicate onto the column and was monitored by
UV-detection at 284 nm. A gradient method was selected rather than an isocratic one to
get faster elution with less retention time. At a flow rate of 1.2 mL min–1, the retention
time was 6.65 min (Fig. 2a). Under the described experimental conditions, the peak was
well defined and free from tailing. RLX was determined by measuring the peak area.
Plot of the mean peak area against concentration gave the linear relationship (R = 0.9991,
N = 5) over the concentration range 50–600 mg mL–1. Using the regression analysis, the
linear equation, Y = –184.40 + 57.88 g was obtained, where Y is the mean peak area and g
is concentration in mg mL–1. The limits of detection and quantification calculated accord-
ing to ICH guidelines were 0.04 and 0.16 mg mL–1, respectively (13).
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Method validation
In order to determine the adequate resolution and reproducibility of the method,
suitability parameters, including retention time, plate number and tailing factor, were
investigated and were found to be 6.65 min, 4047 and 1.72, respectively, which amply
demonstrates the method suitability. Retention time varied for 0.2%.
Specificity. – Specificity of an analytical method may be defined as the ability to un-
equivocally determine the analyte in the presence of additional components such as im-
purities, degradation products and matrix (13–15). Specificity was evaluated by prepar-
ing an analytical placebo and it was confirmed that the signal measured was caused only
by the analyte. A solution of analytical placebo (containing all the tablet excipients ex-
cept RLX) was prepared according to the sample preparation procedure and injected.
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a)
b)
c)
Fig. 2. Chromatograms: a) pure
RLX, b) placebo and c) tablet
extract (300 mg mL–1 RLX).
The resulting chromatogram is shown in Fig. 2b. To identify the interference by these ex-
cipients, the tablet extract after appropriate dilution was chromatographed. The result-
ing chromatogram did not show any peak other than that of RLX (Fig. 2c), which con-
firmed the specificity of the method. In addition, the slope of the calibration curve for
standards was compared with that prepared from the tablet extract. It was found that
there was no significant difference between the slopes, which indicated that excipients
did not interfere with RLX.
Precision. – Precision of the method was evaluated in terms of intra-day and inter-
-day precision (12–14). Three different concentrations of RLX were analyzed in seven re-
plicates on the same day (intra-day precision) and in five consecutive day (inter-day pre-
cision). Within each series, every solution was injected in triplicate. The peak-area based
intra-day RSD values were 0.2–0.5%. The results of the study compiled in Table II are
quite satisfactory. The inter-day precision showed somewhat higher RSD values of 0.6–0.9%.
Intermediate precision was also evaluated by calculating the RSD values of six replicate
determinations performed in standard RLX solutions by three different analysists with
two different instruments. The inter-analyst RSD values were in the range 1.1–1.4% where
the inter-instrument RSD values were 1.0 and 1.1%, respectively, for the two instruments
used.
Accuracy. – Accuracy of an analytical method expresses the closeness between the
reference value and the found value (12–14). The results obtained for er at three concen-
trations (within the linear range) are shown in Table II and were 0.2 to 0.5%. Accuracy
was assessed by analyzing the synthetic mixture (prepared by adding RLX to the pla-
cebo) as described earlier. The calculated percent recovery of the active ingredient was
found to be 99.6 ± 0.8 (n = 5) indicating that the co-formulated substances did not inter-
fere with the assay.
Robustness. – Robustness of the method was checked by deliberately altering two
critical parameters by minor variations: the flow rate was changed from 1.2 mL min–1 to
1.1 mL min–1 and the pH of the mobile phase A was changed from 4.0 to 3.9. The differ-
ences in the retention time and peak area (for a given RLX concentration) caused by the
above minor alterations were insignificant.
Application
The developed and validated method was applied to the determination of RLX in
three brands of tablets, each containing 60 mg per tablet. Evaluation was performed us-
ing the calibration curve method, since no significant difference between the slopes of
the calibration curves for standards and tablet extracts was observed. The results obtained
by the proposed method were statistically compared with those of the literature (UV-
-spectrophotometry) method (8) by applying Student’s t-test for accuracy and F-test for
precision. As shown by the results compiled in Table III, the calculated t- and F-values
did not exceed the tabulated values at the 95% confidence level for four degrees of free-
dom, suggesting that the proposed method and the literature method did not differ sig-
nificantly with respect to accuracy and precision.
The accuracy and validity of the proposed methods were further ascertained by per-
forming recovery experiments. Pre-analyzed tablet powder was spiked with pure RLX
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at three different levels and the total was found by the proposed methods. Each determi-
nation was repeated three times. Recovery of the pure drug added was in the range
97.7–103.2%, with the RSD values of 1.6–2.2%. The results of this study given in Table IV
reveal that the common tablet excipients did not interfere with the determination.
The main features of the method are its wide linear dynamic range, high sensitivity,
as shown by the LOQ value, and high accuracy and precision, as revealed by the reco-
very study and intra-day and inter-day precision studies.
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Table II. Relative error and intra-day precision
RLX taken (mg mL–1) RLX found (mg mL–1)a er (%) RSD (%)b
250 249.5 0.2 0.4
400 398.2 0.5 0.5
550 548.6 0.3 0.2
a Mean value of seven determinations.
b Based on peak area.
Table III. Determination of raloxifene hydrochloride in tablets and comparison with the reference method
Formulation
Nominal
amount (mg)
Found (%)a
Literature method (8) Proposed method t-value F-value
A 60 101.3 ± 0.6 100.8 ± 1.3 0.83 4.33
B 60 98.2 ± 1.1 96.9 ± 1.5 1.62 1.95
C 60 101.5 ± 0.9 102.8 ± 1.6 1.67 3.59
a Mean ± SD, n = 5.
Tabulated t-value at 95% confidence level is 2.77.
Tabulated F-value at 95% confidence level is 6.39.
Table IV. Recovery study
Formulation
studied
RLX in
formulation (g mL–1)
Pure RLX
added (g mL–1)
Total found
(g mL–1)
Pure RLX
recovered (%)a
A
201.6 50 251.75 100.3 ± 1.7
201.6 200 408.00 103.2 ± 1.9
201.6 350 550.90 99.80 ± 2.1
C
205.6 50 255.45 99.7 ± 1.8
205.6 200 401.00 97.7 ± 1.6
205.6 350 560.15 101.3 ± 2.2
aMean ± SD, n = 3.
CONCLUSION
In conclusion, a gradient reversed-phase HPLC-UV assay was developed for the de-
termination of raloxifene and validated as per the current ICH guidelines. The method is
simple, precise and accurate, selective and sufficiently sensitive compared to many simi-
lar methods reported earlier (Table I). Hence, it seems suitable for the determination of
the drug either in bulk or in tablets without interference from commonly used excipients
and could be used in a quality control laboratory.
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S A @ E T A K
Gradijentna HPLC analiza raloksifen hidroklorida
i primjena u kontroli kvalitete
KANAKAPURA BASAVAIAH, URDIGERE RANGACHAR ANIL KUMAR i KALSANG THARPA
Koriste}i gradijentnu teku}insku kromatografiju visoke u~inkovitosti razvijena je
brza, osjetljiva i selektivna metoda za odre|ivanje raloksifen hidroklorida (RLX), ~iste
supstancije i u tabletama. U radu je primijenjena reverzno-fazna kolona Hypersil ODS te
UV detekcija pri 284 nm. Standardna krivulja bila je linearna (R = 0,999) u koncentracij-
skom podru~ju 50600 mg mL1. Granica detekcije bila je 0,04 mg mL1 a granica odre|i-
vanja 0,16 mg mL1. Repetabilnost, intermedijalna preciznost i ispravnost ispitivane su
prema va`e}im ICH uputama. Mjerenjem povr{ine ispod pika na tri koncentracijske ra-
zine (250, 450 i 550 mg mL1) procijenjena je repetabilnost na 0,20,5%. Relativna pog-
re{ka procijenjena unutar jednog dana (er) bila je izme|u 0,2 i 0,5%. Razvijena metoda
uspje{no je primijenjena za odre|ivanje RLX u tabletama. Rezultati su statisti~ki uspore-
|eni s rezultatima dobivenim prema ranije objavljenoj metodi. Analiti~ki povrat bio je u
rasponu 97,7103,2 uz preciznost od 1,6 do 2,2%. Nije primije}ena interferencija pomo}-
nih tvari. Metoda je ekonomi~na s obzirom na utro{eno vrijeme i koli~ine upotrebljenog
otapala.
Klju~ne rije~i: raloksifen hidroklorid, gradijentna HPLC, ljekoviti pripravci
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